Literature DB >> 2229757

Plasma homocyst(e)ine levels in men with premature coronary artery disease.

J J Genest1, J R McNamara, D N Salem, P W Wilson, E J Schaefer, M R Malinow.   

Abstract

Plasma homocyst(e)ine (that is, the sum of free and bound homocysteine and its oxidized forms, homocystine and homocysteine-cysteine mixed disulfide) levels were determined in 170 men (mean age +/- SD 50 +/- 7 years) with premature coronary artery disease diagnosed at coronary angiography and in 255 control subjects clinically free of coronary artery disease (mean age 49 +/- 6 years). Patients with coronary artery disease had a higher homocyst(e)ine level than control subjects (13.66 +/- 6.44 versus 10.93 +/- 4.92 nmol/ml, p less than 0.001). High density lipoprotein (HDL) cholesterol levels were lower (32 +/- 10 versus 46 +/- 13 mg/dl, p less than 0.001) and triglycerides levels were higher (193 +/- 103 versus 136 +/- 106 mg/dl, p less than 0.001) in the coronary disease group. Plasma total cholesterol and low density lipoprotein (LDL) cholesterol levels were not significantly different between patients with coronary disease and control subjects. The presence of hypertension, smoking or diabetes mellitus did not significantly alter homocyst(e)ine levels in the patient or the control group. Patients who were not taking a beta-adrenergic blocking drug (n = 70) had a nonsignificantly higher homocyst(e)ine level than did patients taking this class of drugs (n = 100) (14.67 +/- 8.92 versus 12.95 +/- 3.77 nmol/ml, p = 0.087). By design, none of the control subjects were taking a beta-blocker. No significant correlations were observed between homocyst(e)ine and age, serum cholesterol, LDL cholesterol, HDL cholesterol or triglyceride levels. It is concluded that an elevated plasma homocyst(e)ine level is an independent risk factor for the development of premature coronary atherosclerosis in men.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229757     DOI: 10.1016/0735-1097(90)90542-w

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease.

Authors:  J B Ubbink; W J Vermaak; J M Bennett; P J Becker; D A van Staden; S Bissbort
Journal:  Klin Wochenschr       Date:  1991-08-16

2.  Total plasma homocysteine: influence of some common physiological variables.

Authors:  I Fermo; E De Vecchi; S V D'Angelo; A D'Angelo; R Paroni
Journal:  Amino Acids       Date:  1993-02       Impact factor: 3.520

3.  Novel risk stratification and treatment.

Authors:  Takaaki Komatsu; Shiro Nakahara; Isao Taguchi
Journal:  Hypertens Res       Date:  2016-04-14       Impact factor: 3.872

4.  Polymorphisms in methionine synthase reductase and betaine-homocysteine S-methyltransferase genes: risk of placental abruption.

Authors:  Cande V Ananth; Denise A Elsasser; Wendy L Kinzler; Morgan R Peltier; Darios Getahun; Daniel Leclerc; Rima R Rozen
Journal:  Mol Genet Metab       Date:  2007-03-26       Impact factor: 4.797

5.  Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.

Authors:  M Watanabe; J Osada; Y Aratani; K Kluckman; R Reddick; M R Malinow; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Contribution of dietary intakes of antioxidants to homocysteine-induced low density lipoprotein (LDL) oxidation in atherosclerotic patients.

Authors:  Hongseog Seo; Hyunhee Oh; Hyesoon Park; Miyoung Park; Yangsoo Jang; Myoungsook Lee
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

7.  Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.

Authors:  K A Hajjar
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

8.  Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease?

Authors:  L Thuillier; B Chadefaux-Vekemans; J P Bonnefont; A Kara; J Aupetit; C Rochette; G Montalescot; M C Couty; P Kamoun; A Ankri
Journal:  J Inherit Metab Dis       Date:  1998-12       Impact factor: 4.982

Review 9.  Abiotrophic gene action in Homo sapiens: potential mechanisms and significance for the pathobiology of aging.

Authors:  G M Martin
Journal:  Genetica       Date:  1993       Impact factor: 1.082

10.  Hyperhomocysteinemia and the response to vitamin supplementation.

Authors:  J B Ubbink; A van der Merwe; W J Vermaak; R Delport
Journal:  Clin Investig       Date:  1993-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.